Cellebrite DI Spring 2026 Release Tests Undervalued Stock Story - Yahoo Finance Singapore

Cellebrite DI Spring 2026 Release Tests Undervalued Stock Story Simply Wall St Sat, 25 April 2026 at 7:05 am GMT-4 3 min read CLBT -0.24% Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Cellebrite DI (NasdaqGS:CLBT) has rolled out its Spring 2026 Release. The update broadens support for a wider range of iOS and Android devices, including iPhone 17 and iOS 26. The release also adds integration with Corellium on Google Cloud for digital investigations. Cellebrite DI, trading at $12.7, is updating its product suite at a time when its share price has seen a 28.8% decline year to date and a 35.3% decline over the past year. Over a 3 year period, the stock shows a 134.8% gain, while the 5 year return is 27.8%. This provides investors with a mix of longer term gains and more recent pressure. For anyone tracking NasdaqGS:CLBT, this backdrop frames how the Spring 2026 Release might be viewed. The broader device coverage and Google Cloud integration could influence how law enforcement, enterprise security teams, and other customers assess Cellebrite DI's offerings over time. For investors, a key consideration is whether this type of product update helps the company translate current product momentum into steadier demand and more stable sentiment around the stock. Stay updated on the most important news stories for Cellebrite DI by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Cellebrite DI. NasdaqGS:CLBT Earnings & Revenue Growth as at Apr 2026 📰 Beyond the headline: 0 risks and 4 things going right for Cellebrite DI that every investor should see. Investor Checklist: How the Spring 2026 Release Fits the Story Quick Assessment ✅ Price vs Analyst Target: At US$12.70 versus a consensus target of US$21.67, the stock trades about 41% below analyst expectations. ✅ Simply Wall St Valuation: Simply Wall St flags the shares as undervalued, trading 21.7% below its estimated fair value. ❌ Recent Momentum: The 30 day return of roughly 10.3% decline shows sentiment has been weak recently. There is only one way to know the right time to buy, sell or hold Cellebrite DI. Head to Simply Wall St's company report for the latest analysis of Cellebrite DI's Fair Value. Key Considerations 📊 Expanded support for iPhone 17, iOS 26 and more Android devices, plus Corellium on Google Cloud, may help Cellebrite DI stay relevant for digital investigations as devices evolve. 📊 With a P/E of 40.7 versus a Software industry average of 30.5 and revenue of US$475.7m, investors may want to watch how future earnings and revenue trends relate to this premium and the product rollout. ⚠️ The recent 10.3% decline in the share price means execution on this release and customer adoption will likely be closely monitored for any indication that weakness in sentiment is continuing. Story continues Terms and Privacy Policy Privacy dashboard